HUMA
Humacyte, Inc.NASDAQHealthcare$0.64+8.53%ClosedMarket Cap: $100.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
33.07
P/S
50.00
EV/EBITDA
-1.16
DCF Value
$-0.02
FCF Yield
-104.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-736.5%
Operating Margin
-5306.0%
Net Margin
-2003.6%
ROE
-424.8%
ROA
-35.1%
ROIC
-107.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $467.0K | -2627.0% | $-30.8M | $-24.8M | $-0.15 | — |
| FY 2025 | $2.0M | -736.5% | $-107.4M | $-40.8M | $-0.26 | — |
| Q3 2025 | $753.0K | 65.5% | $-24.4M | $-17.5M | $-0.11 | — |
| Q2 2025 | $301.0K | -588.7% | $-29.7M | $-37.7M | $-0.24 | — |
| Q1 2025 | $517.0K | -282.8% | $-23.2M | $39.1M | $0.28 | — |
| Q4 2024 | $7.2M | 50.0% | $-28.1M | $-20.9M | $-0.16 | — |
| FY 2024 | $0.00 | -Infinity% | $-114.4M | $-148.7M | $-1.26 | — |
| Q3 2024 | $0.00 | -Infinity% | $-30.2M | $-39.2M | $-0.33 | — |
| Q2 2024 | $0.00 | -Infinity% | $-29.5M | $-56.7M | $-0.48 | — |
| Q1 2024 | $0.00 | -Infinity% | $-26.6M | $-31.9M | $-0.29 | — |
| Q4 2023 | $0.00 | -Infinity% | $-26.2M | $-25.1M | $-0.24 | — |
| FY 2023 | $0.00 | -Infinity% | $-100.0M | $-110.8M | $-1.07 | — |